FDA 510(k) pathway for LATAM medical device exporters: predicate device is key

The U.S. Food and Drug Administration (FDA) requires most medical devices entering the U.S. market to undergo a premarket review. For many devices from Latin America, the 510(k) premarket notification pathway is the most common route. This guide explains what the 510(k) process covers, who it applies to, and how LATAM exporters can navigate it successfully.

What the 510(k) Process Covers

The 510(k) premarket notification is a submission to the FDA demonstrating that a medical device is substantially equivalent to a legally marketed predicate device. It does not require clinical trials for most devices, but it does demand robust technical documentation. The FDA reviews the device's intended use, technological characteristics, and performance data. This pathway applies to moderate-risk devices classified as Class II, such as infusion pumps, surgical gloves, and diagnostic imaging equipment. Some Class I devices also require 510(k) clearance if they are not exempt. LATAM exporters must determine their device's classification using the FDA's Product Code database before starting.

Who Needs to Submit a 510(k)

Any foreign manufacturer planning to export a medical device to the United States must comply with the 510(k) requirements if the device is not exempt. This includes manufacturers in Mexico, Brazil, Colombia, Chile, Argentina, and other LATAM countries. The FDA does not distinguish between domestic and foreign manufacturers regarding premarket notification. However, foreign manufacturers must designate a U.S. agent or authorized representative to handle FDA communications. The U.S. agent must be a resident of the United States or a business entity located there. Coppermont frequently advises LATAM firms on selecting and working with qualified U.S. agents to streamline this requirement.

Step-by-Step Compliance Process

The 510(k) pathway involves several distinct stages. First, classify your device by searching the FDA's Product Classification Database. Confirm that your device requires a 510(k) and is not exempt. Next, identify a suitable predicate device that is already legally marketed in the U.S. The predicate must have the same intended use and similar technological characteristics. Then, gather all required documentation, including device description, labeling, biocompatibility testing, electrical safety reports, and performance data. Prepare a 510(k) summary or statement and compile the submission in electronic format using the FDA's eSubmitter tool. Submit the application through the FDA's electronic submission gateway. The FDA will assign a review team and may request additional information through an AI (Additional Information) letter. Respond promptly and thoroughly. Once cleared, the device is listed in the FDA's 510(k) database, and you can begin marketing.

Timelines and Costs

The FDA aims to review 510(k) submissions within 90 days of receipt, but actual timelines vary. Simple submissions with complete data may be cleared in 60 to 90 days. Complex devices or those requiring additional data can take 6 to 12 months. The FDA charges a user fee for 510(k) submissions. As of 2025, the standard fee is approximately $21,000 for most applicants. Small businesses with annual gross revenues under $100 million may qualify for a reduced fee of around $5,250. LATAM exporters should budget for additional costs: U.S. agent fees ($1,000 to $3,000 per year), testing and certification costs ($10,000 to $50,000 depending on device complexity), and legal or consulting fees for submission preparation ($5,000 to $30,000). Coppermont helps LATAM firms estimate these costs accurately and identify small business fee reductions where applicable.

Common Mistakes That Delay Clearance

Many LATAM exporters encounter avoidable pitfalls. One frequent mistake is selecting an inappropriate predicate device that does not match the intended use or technological characteristics. Another is submitting incomplete or poorly organized technical documentation, especially regarding biocompatibility and electrical safety testing. Failing to provide clear labeling in English is also common. Additionally, some manufacturers underestimate the importance of quality system compliance with FDA's Quality System Regulation (QSR) or ISO 13485. Not responding to FDA AI letters within the required timeframe can lead to automatic withdrawal. Finally, neglecting to register the establishment and list the device with the FDA before marketing is a critical error. Working with an experienced regulatory partner like Coppermont can help you avoid these issues and keep your submission on track.

Regional Variations and Considerations

LATAM countries have their own medical device regulatory frameworks, such as ANVISA in Brazil and COFEPRIS in Mexico. While these systems share some similarities with the FDA, they are not interchangeable. For example, ANVISA requires Good Manufacturing Practices (GMP) certification, which may not directly satisfy FDA requirements. LATAM exporters should not assume that national approvals automatically expedite FDA clearance. However, leveraging existing testing and documentation from local approvals can reduce duplication. Coppermont advises clients on how to align their local compliance efforts with FDA expectations to save time and money.

Connecting Compliance to Coppermont's Advisory Service

Navigating the FDA 510(k) pathway from Latin America requires careful planning and local expertise. Coppermont provides end-to-end regulatory guidance for LATAM medical device exporters, from classification and predicate selection to submission preparation and U.S. agent coordination. Our team understands the regulatory landscapes of both the U.S. and LATAM markets, helping you avoid common pitfalls and accelerate your time to clearance. Whether you are a first-time exporter or seeking to expand your product portfolio, Coppermont can tailor a compliance strategy that fits your device and your budget. Contact us today to discuss your 510(k) submission and take the next step toward U.S. market entry.